This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Poland’s pharmacy ad ban violates EU law, top court judges rule

By Júlia Tar ( June 19, 2025, 09:45 GMT | Insight) -- Poland’s ban on pharmacy advertising breaches EU rules by unjustifiably restricting pharmacists’ ability to promote their services online, the bloc’s top court ruled today. While professional standards may limit how such advertising is carried out, they cannot be used to impose a total prohibition, the judges said. The ban also undermines single market freedoms by making it harder for foreign-based pharmacists to enter the Polish market. The decision follows the European Commission’s referral to the court in 2023, alleging Poland’s pharmacy advertising breaches EU internal market rules.Provisions of the Polish pharmaceutical law that impose a ban on advertising by pharmacies and on the promotion of their services violate EU law, according to today’s ruling by the Court of Justice of the EU (see here)....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections